| Article Access Statistics|
| Viewed||5134 |
| Printed||218 |
| Emailed||0 |
| PDF Downloaded||37 |
| Comments ||[Add] |
| Cited by others ||9 |
Click on image for details.
|Year : 2017 | Volume
| Issue : 4 | Page : 226-231
Insomnia and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis
K Wijarnpreecha1, C Thongprayoon1, P Panjawatanan2, P Ungprasert3
1 Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY, USA
2 Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
3 Department of Internal Medicine, Division of Rheumatology, Rochester, Minnesota, USA; Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
|Date of Submission||11-Mar-2017|
|Date of Decision||15-Apr-2017|
|Date of Acceptance||16-May-2017|
|Date of Web Publication||11-Oct-2017|
Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY
Source of Support: None, Conflict of Interest: None
Aim: This sudy aims to investigate the association between insomnia or excessive daytime sleepiness (EDS) and risk of nonalcoholic fatty liver disease (NAFLD). Methods: We searched published studies indexed in MEDLINE and EMBASE database from inception to December 2015. Studies that reported odds ratios (ORs), risk ratios, hazard ratios or standardized incidence ratio with 95% confidence intervals (CI) comparing the risk of NAFLD among participants who had insomnia or EDS versus those without insomnia or EDS were included. Pooled ORs and 95% CI were calculated using a random-effect, generic inverse variance method of DerSimonian and Laird. Cochran's Q test and I2 statistic were used to determine the between-study heterogeneity. Results: Our search strategy yielded 2117 potentially relevant articles (781 articles from MEDLINE and 1336 articles from EMBASE). After comprehensive review, seven studies (three cross-sectional studies and four case–control studies) were found to be eligible and were included in the meta-analysis. The risk of NAFLD in participants who had insomnia was significantly higher with the pooled OR of 1.13 (95% CI, 1.00–1.27). The statistical heterogeneity was moderate with an I2 of 62%. Elevated risk of NAFLD was also observed among participants with EDS even though the 95% CI was wider and did not reach statistical significance (pooled OR 2.21; 95% CI, 0.84–5.82). The statistical heterogeneity was moderate with an I2 of 62%. Conclusions: Our study demonstrated an increased risk of NAFLD among participants who had insomnia or EDS. Whether this association is causal needs further investigations.
Keywords: Insomnia, meta.analysis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, sleep quality
|How to cite this article:|
Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Insomnia and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. J Postgrad Med 2017;63:226-31
|How to cite this URL:|
Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Insomnia and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. J Postgrad Med [serial online] 2017 [cited 2023 Feb 1];63:226-31. Available from: https://www.jpgmonline.com/text.asp?2017/63/4/226/213895
| :: Introduction|| |
Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic hepatitis and cirrhosis in Western countries as the prevalence of obesity has been steadily increasing over the past few decades. Pathology of NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH) which can ultimately progress to cirrhosis. Metabolic syndrome and insulin resistance are the prime risk factors for NAFLD., Other risk factors include hypertension, dyslipidemia, polycystic ovary syndrome, and hypothyroidism.,
Insomnia and excessive daytime sleepiness (EDS), defined as the inability to maintain wakefulness and alertness during the major waking episodes of the day with sleep occurring unintentionally almost daily for at least 3 months, are ones of the most common sleep-related disorders in adults., Many studies have shown an association between both conditions and adverse health outcomes including the increased risk of psychiatric disorders, drug abuses, diabetes, cardiovascular disease as well as increased incidence of motor vehicle accident.,,,,
Interestingly, insomnia and EDS could also increase the risk of NAFLD as observed in several epidemiologic studies.,,,,,, Nonetheless, the results of those studies were inconsistent. To further investigate this possible association, we conducted this systematic review and meta-analysis of observational studies reporting the risk of NAFLD among those who had insomnia or EDS.
| :: Methods|| |
Two investigators (K.W. and P.U.) independently searched published studies indexed in MEDLINE and EMBASE database from inception to December 2015 using the search strategy that included the terms for “sleep” and “NAFLD” as described in [Online Supplementary Data 1 available online [Additional file 1]]. No language limitation was applied. A manual search for additional studies using references of selected retrieved articles was also performed.
The inclusion criteria were as follows: (1) case–control, cross-sectional, or cohort studies evaluating the association between insomnia or EDS and NAFLD, (2) odds ratios (ORs), risk ratios, hazard ratios or standardized incidence ratio with 95% confidence intervals (CI) were provided, and (3) participants without insomnia or EDS were used as comparators in cohort study while participants without NAFLD were used as comparators in case–control and cross-sectional study.
Study eligibility was independently determined by the two investigators noted above. Differences in the determination of study eligibility were resolved by mutual consensus. The quality of each study was also independently evaluated by each investigator using Newcastle–Ottawa quality assessment scale. This scale evaluated each study in three domains including the selection of the participants, the comparability between the groups and the ascertainment of the exposure for case–control study and the outcome of interest for cohort study. The modified Newcastle–Ottawa scale as described by Herzog et al. was used for cross-sectional study.
A standardized data collection form was used to extract the following data from each study: Title of the study, name of the first author, year of study, year of publication, country of origin, number of participants, demographic data of the participants, methods used to identify and verify the insomnia, EDS and NAFLD, adjusted effect estimates with 95% CI and covariates that were adjusted in the multivariate analysis.
To ensure the accuracy, this data extraction process was independently performed by all investigators. Data discrepancy was resolved by referring to the original articles.
Data analysis was performed using Review Manager 5.3 Software from the Cochrane Collaboration (London, United Kingdom). Adjusted point estimates and standard errors from the individual study were combined using the generic inverse variance method of DerSimonian and Laird, which assigned the weight of each study based on its variance. In light of the high likelihood of between-study variance because of different study designs and populations, we used a random-effect model rather than a fixed-effect model. Cochran's Q test and I2 statistic were used to determine the between-study heterogeneity. A value of I2 of 0%–25% represents insignificant heterogeneity, >25% but <50% represents low heterogeneity, >50% but <75% represents moderate heterogeneity, and >75% represents high heterogeneity.
| :: Results|| |
Our search strategy yielded 2117 potentially relevant articles (781 articles from MEDLINE and 1,336 articles from EMBASE). After the exclusion of 723 duplicated articles, 1394 of them underwent title and abstract review. A total of 1341 articles were excluded at this stage since they were case report, letter to editor, review article or interventional study, leaving 53 articles for a full-length article review. Forty of them were excluded since they did not report the outcome of interest while six articles were excluded since they were descriptive studies without comparators. Therefore, seven studies (three cross-sectional studies and four case–control studies) met our eligibility criteria and were included in the meta-analysis.,,,,,, [Figure 1] outlines the literature review and study selection process. The characteristics and quality assessment of the included studies of insomnia and EDS are described respectively in [Table 1] and [Table 2]. PRISMA (Preferred reporting Items for Systematic Reviews and Meta-Analysis) is provided as [Online Supplementary Data 2 available online [Additional file 2] ]. It should be noted that the inter-rater agreement for the quality assessment was high with the kappa statistics of 0.75.
|Table 1: Main characteristics of the studies included in this meta-analysis of the association between insomnia or poor sleep quality and nonalcoholic fatty liver disease|
Click here to view
|Table 2: Main characteristics of the studies included in this meta-analysis of the association between excessive daytime sleepiness and nonalcoholic fatty liver disease|
Click here to view
We found a significantly increased risk of NAFLD among participants with insomnia with the pooled OR of 1.13 (95% CI, 1.00–1.27), as shown in [Figure 2]. The statistical heterogeneity was moderate with an I2 of 62%. We also found an increased risk of NAFLD among participants with EDS with the pooled OR of 2.21 even though the 95% CI was wider and did not reach statistical significance (95% CI, 0.84–5.82), as shown in [Figure 3]. The statistical heterogeneity was moderate with an I2 of 62%.
|Figure 2: Forest plot of all included studies of the association between insomnia or poor sleep quality and nonalcoholic fatty liver disease|
Click here to view
|Figure 3: Forest plot of all included studies of the association between excessive daytime sleepiness and nonalcoholic fatty liver disease|
Click here to view
Evaluation for publication bias
We did not perform an evaluation for publication bias as the number of studies included in the meta-analyses was too small.
| :: Discussion|| |
The association between insomnia/EDS and risk of NAFLD has been observed in epidemiologic studies even though the results were inconsistent. This meta-analysis was conducted with the aims to summarize all available data. We found a small but significantly increased risk of NAFLD among participants who had insomnia compared to those with good sleeping. We also found an increased risk of NAFLD among participants with EDS even though the result did not reach statistical significance due to a smaller number of included studies. The mechanism behind this association remains unknown, but there are some potential explanations.
First, it has been shown that several inflammatory cytokines essential for the pathogenesis of NAFLD, such as interleukin-6 and tumor necrotic factor alpha, are inducible by lack of sleep.,, These cytokines can increase adipocyte lipolysis, resulting in hepatic overflow of free fatty acid, and impaired insulin signaling. Second, insomnia may increase appetite as a result of hormonal changes such as increased ghrelin level and decreased leptin level, leading to more calories intake and obesity, the major risk factor for NAFLD., Third, insomnia and EDS are associated with fatigue. Therefore, those with insomnia or EDS might be less physically active and are at higher risk of obesity and metabolic syndrome.
Although the quality of included studies was high as reflected by the high Newcastle–Ottawa scores, we acknowledged that there were some limitations.
First, data on insomnia and EDS may be less reliable as most included studies used self-administered questionnaires. Second, the statistical heterogeneity was moderate in this meta-analysis. We suspect that the differences in study designs, populations, and methods used to verify NAFLD were responsible for this inter-study variability. Third, about half of the included studies were cross-sectional studies that would not allow us to establish a temporal relationship between NAFLD and sleep disturbance. It is possible that NAFLD might have negative effects on physiology of sleep and the insomnia/EDS are a consequence of NAFLD, not risk factors for NAFLD. In fact, this study is a meta-analysis of observational studies that, at best, could only demonstrate an association but cannot prove causality as unknown confounders could play a certain role behind the association.
In summary, an increased risk of NAFLD was observed among participants who had insomnia or EDS. Whether this association is causal remains unclear. Further investigations are required to establish the role of sleep for the prevention of NAFLD.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| :: References|| |
Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: Common pathophysiologic mechanisms. Curr Diab Rep 2015;15:607.
Wijarnpreecha K, Thongprayoon C, Edmonds PJ, Cheungpasitporn W. Associations of sugar- and artificially sweetened soda with nonalcoholic fatty liver disease: A systematic review and meta-analysis. QJM 2016;109:461-6.
Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol 2015;62 1 Suppl:S47-64.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al.
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609.
Kiejna A, Wojtyniak B, Rymaszewska J, Stokwiszewski J. Prevalence of insomnia in Poland-results of the National Health Interview Survey. Acta Neuropsychiatr 2003;15:68-73.
Kronholm E, Partonen T, Härmä M, Hublin C, Lallukka T, Peltonen M, et al.
Prevalence of insomnia-related symptoms continues to increase in the Finnish working-age population. J Sleep Res 2016;25:454-7.
Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med 1998;60:610-5.
Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-8.
Fernandez-Mendoza J, Vgontzas AN, Liao D, Shaffer ML, Vela-Bueno A, Basta M, et al.
Insomnia with objective short sleep duration and incident hypertension: The Penn State Cohort. Hypertension 2012;60:929-35.
Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Bixler EO. Insomnia with objective short sleep duration is associated with type 2 diabetes: A population-based study. Diabetes Care 2009;32:1980-5.
Young TB. Epidemiology of daytime sleepiness: Definitions, symptomatology, and prevalence. J Clin Psychiatry 2004;65 Suppl 16:12-6.
Bernsmeier C, Weisskopf DM, Pflueger MO, Mosimann J, Campana B, Terracciano L, et al.
Sleep disruption and daytime sleepiness correlating with disease severity and insulin resistance in non-alcoholic fatty liver disease: A comparison with healthy controls. PLoS One 2015;10:e0143293.
Hsieh SD, Muto T, Murase T, Tsuji H, Arase Y. Association of short sleep duration with obesity, diabetes, fatty liver and behavioral factors in Japanese men. Intern Med 2011;50:2499-502.
Kallwitz ER, Daviglus ML, Allison MA, Emory KT, Zhao L, Kuniholm MH, et al.
Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage. Clin Gastroenterol Hepatol 2015;13:569-76.
Kim CW, Yun KE, Jung HS, Chang Y, Choi ES, Kwon MJ, et al.
Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses. J Hepatol 2013;59:351-7.
Mir HM, Stepanova M, Afendy H, Cable R, Younossi ZM. Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A population-based study. J Clin Exp Hepatol 2013;3:181-5.
Pulixi EA, Tobaldini E, Battezzati PM, D'Ingianna P, Borroni V, Fracanzani AL, et al.
Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease. PLoS One 2014;9:e96349.
Yu JH, Ahn JH, Yoo HJ, Seo JA, Kim SG, Choi KM, et al.
Obstructive sleep apnea with excessive daytime sleepiness is associated with non-alcoholic fatty liver disease regardless of visceral fat. Korean J Intern Med 2015;30:846-55.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5.
Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 2013;13:154.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al.
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412-21.
Prather AA, Marsland AL, Hall M, Neumann SA, Muldoon MF, Manuck SB. Normative variation in self-reported sleep quality and sleep debt is associated with stimulated pro-inflammatory cytokine production. Biol Psychol 2009;82:12-7.
Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103:1372-9.
Langin D, Arner P. Importance of TNFalpha and neutral lipases in human adipose tissue lipolysis. Trends Endocrinol Metab 2006;17:314-20.
Spiegel K, Leproult R, L'hermite-Balériaux M, Copinschi G, Penev PD, Van Cauter E. Leptin levels are dependent on sleep duration: Relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab 2004;89:5762-71.
Spiegel K, Tasali E, Leproult R, Scherberg N, Van Cauter E. Twenty-four-hour profiles of acylated and total ghrelin: Relationship with glucose levels and impact of time of day and sleep. J Clin Endocrinol Metab 2011;96:486-93.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2]
|This article has been cited by|
||Short sleep duration and the risk of nonalcoholic fatty liver disease/metabolic associated fatty liver disease: a systematic review and meta-analysis
| ||Jie Yang, Kuo Zhang, Ziwei Xi, Yue Ma, Chunli Shao, Wenyao Wang, Yi-Da Tang |
| ||Sleep and Breathing. 2022; |
|[Pubmed] | [DOI]|
||Non-alcoholic fatty liver disease, sleep behaviors, and incident type 2 diabetes
| ||Haojie Zhang, Yuying Wang, Chi Chen, Bin Wang, Jie Chen, Xiao Tan, Fangzhen Xia, Jihui Zhang, Yingli Lu, Ningjian Wang |
| ||Journal of Gastroenterology and Hepatology. 2022; |
|[Pubmed] | [DOI]|
||The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm
| ||Sebastian Larion, Caleb A. Padgett, Joshua T. Butcher, James D. Mintz, David J. Fulton, David W. Stepp |
| ||American Journal of Physiology-Gastrointestinal and Liver Physiology. 2022; 323(4): G387 |
|[Pubmed] | [DOI]|
||Sleep Factors in Relation to Metabolic Dysfunction-Associated Fatty Liver Disease in Middle-Aged and Elderly Chinese
| ||Jialu Yang, Shiyun Luo, Rui Li, Jingmeng Ju, Zhuoyu Zhang, Jichuan Shen, Minying Sun, Jiahua Fan, Min Xia, Wei Zhu, Yan Liu |
| ||The Journal of Clinical Endocrinology & Metabolism. 2022; |
|[Pubmed] | [DOI]|
||Investigating the Association Between Seven Sleep Traits and Nonalcoholic Fatty Liver Disease: Observational and Mendelian Randomization Study
| ||Hong Fan, Zhenqiu Liu, Xin Zhang, Huangbo Yuan, Xiaolan Zhao, Renjia Zhao, Tingting Shi, Sheng Wu, Yiyun Xu, Chen Suo, Xingdong Chen, Tiejun Zhang |
| ||Frontiers in Genetics. 2022; 13 |
|[Pubmed] | [DOI]|
||Cerebrovascular alterations in NAFLD: Is it increasing our risk of Alzheimer's disease?
| ||Anna Hadjihambi |
| ||Analytical Biochemistry. 2021; : 114387 |
|[Pubmed] | [DOI]|
||The overlooked vital sign: the importance of measuring sleep in drug development studies
| ||Marie McCarthy, Patricia Murphy, Russell Rosenberg, Colin Orford |
| ||Drug Discovery Today. 2021; |
|[Pubmed] | [DOI]|
||Insomnia affects the levels of plasma bilirubin and protein metabolism: an observational study and GWGEIS in UK Biobank cohort
| ||Xiaomeng Chu, Li Liu, Jing Ye, Yan Wen, Ping Li, Bolun Cheng, Shiqiang Cheng, Lu Zhang, Xin Qi, Mei Ma, Chujun Liang, Om Prakash Kafle, Cuiyan Wu, Sen Wang, Xi Wang, Yujie Ning, Feng Zhang |
| ||Sleep Medicine. 2021; 85: 184 |
|[Pubmed] | [DOI]|
tuber: bioconstituents, processing, products, and health benefits
| ||Yang Zhang, Guihong Yang, Xinyu Wang, Gaoyang Ni, Zhumei Cui, Zhaowei Yan |
| ||Journal of the Science of Food and Agriculture. 2021; 101(8): 3085 |
|[Pubmed] | [DOI]|